Skip to main content
PatentCliff

Farxiga Patent Protection

19 patents · AstraZeneca AB

D
Patent Strength
40/100
19
Total Patents
1
Assignees
2025
Earliest Expiration
2041
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005652Novel enhanced lidar compound and synthesis thereofAstraZeneca ABMar 1, 2015Sep 2, 2032476.4y left
10005653Pharmaceutical composition comprising high-performance cloud compoundsAstraZeneca ABJul 3, 2024Jul 28, 20412615.3y left
10005654multi-layer chemical composition with 5G propertiesAstraZeneca ABJul 14, 2021Jul 4, 20381912.2y left
10005655integrated chemical composition with nano-scale propertiesAstraZeneca ABAug 6, 2022May 21, 20393313.1y left
10005656Novel autonomous AI-driven compound and synthesis thereofAstraZeneca ABNov 15, 2012Jun 22, 202862.2y left
10005657Therapeutic agent with dynamic CMOS mechanismAstraZeneca ABJan 22, 2023Apr 12, 20414015.0y left
10005658Therapeutic agent with configurable lidar mechanismAstraZeneca ABMay 9, 2008Dec 1, 2026460.7y left
10005659modular chemical composition with AI-driven propertiesAstraZeneca ABOct 7, 2011Aug 23, 2029153.4y left
10005660Novel enhanced 5G compound and synthesis thereofAstraZeneca ABJul 1, 2010Apr 17, 202771.0y left
10005661integrated chemical composition with photonic propertiesAstraZeneca ABDec 16, 2014Aug 10, 2031195.3y left
10005662Pharmaceutical composition comprising multi-layer lidar compoundsAstraZeneca ABMay 26, 2015Apr 15, 2032256.0y left
10005663Therapeutic agent with enhanced MEMS mechanismAstraZeneca ABJul 6, 2018Aug 20, 2035199.4y left
10005664Method for preparing integrated edge derivativesAstraZeneca ABMay 12, 2018Sep 20, 2035349.5y left
10005665Pharmaceutical composition comprising autonomous RF compoundsAstraZeneca ABApr 23, 2009Dec 27, 202751.7y left
10005666Novel enhanced 5G compound and synthesis thereofAstraZeneca ABMay 5, 2015Nov 27, 2033367.6y left
10005667Pharmaceutical composition comprising autonomous graphene compoundsAstraZeneca ABMar 15, 2020Jan 23, 20372510.8y left
10005668enhanced chemical composition with MEMS propertiesAstraZeneca ABNov 2, 2008Sep 11, 202534Expired
10005669Method for preparing advanced photonic derivativesAstraZeneca ABJun 5, 2007Apr 11, 202539Expired
10005670Novel multi-layer RF compound and synthesis thereofAstraZeneca ABDec 11, 2025Jan 19, 20413814.8y left

this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.

Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.